苏沃雷生与艾司唑仑治疗顽固性失眠疗效比较  

The comparison of clinical effectiveness between suvorexant and estazolam for treating intractable insomnia

作　　者：范百亚 康静[1] 贺亚龙[1] 郝美美[1] 杜伟[1] FAN Baiya KANG Jing HE Yalong HAO Meimei DU Wei(Department of Neurology, the People＇s Hospital of Yan＇ an, Shaanxi Province, Yan＇ an 716000, China)

机构地区：[1]延安市人民医院神经内科,716000

出　　处：《疑难病杂志》2017年第2期127-129,133,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的比较苏沃雷生与艾司唑仑片治疗顽固性失眠的临床疗效和安全性。方法选择2015年1月—2016年4月延安市人民医院神经内科收治顽固性失眠患者36例作为研究对象,根据随机数字表法分为观察组和对照组,每组18例。观察组患者给予苏沃雷生治疗,对照组患者给予艾司唑仑片治疗,2组疗程均为4周。疗效评定采用总有效率和匹兹堡睡眠质量指数(PSQI)进行评价。同时,密切观察并记录治疗期间患者的不良反应发生情况。结果观察组总有效率高于对照组(94.4%vs.55.6%,x^2=32.541,P=0.020)。治疗前,2组患者的PSQI评分比较,差异无统计学意义(P>0.05);治疗后,观察组和对照组PSQI量表睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠障碍、日间功能和总评分分别为(1.22±0.47)分vs.(1.81±0.59)分、(1.44±0.52)分vs.(1.90±0.50)分、(1.54±0.61)分vs.(2.01±0.72)分、(1.24±0.53)分vs.(1.72±0.65)分、(1.15±0.49)分vs.(1.55±0.62)分、(0.92±0.45)分vs.(1.71±0.58)分、(7.98±3.44)分vs.(10.26±3.38)分,观察组均显著低于治疗前,而对照组仅入睡时间及总评分显著降低,且观察组各项指标均低于对照组(P<0.05)。2组不良反应比较,差异均无统计学意义(27.8%vs.22.2%,x^2=11.533,P=0.700)。结论苏沃雷生治疗顽固性失眠的疗效优于艾司唑仑片而不良反应相似,值得临床推广应用。Objective To assess the effectiveness and safely of suvorexanl compared with estazolam for treating intractable insomnia（ITIS）.Methods Thirl） six ITIS participants were recruited from department of neurology,People＇s hospital of Yan＇an from January 2015 to April 2016.and they uere randomly divided into the intervention group（18 subjects） and the control group（18 subjects）.The patients in the intervention group uere received suvorexanl,while the subjects in the control group were received Estazolam.Patients in both groups were treated for 4 weeks.The outcomes include total efficacy rale.Pittsburgh sleep quality index（PSQI） and adverse events uere compared.Results The total effect rale（94.4%） in the intervention group was higher than that the control group 55.6%（P〈0.05）.The comparison of PSQI was not different between two groups bofore treatmenl（P〉0.05）.The significant differences were found between two groups in I＇SOl scores after treatment（P〈0.05）,which including：sleep quality（1.22 ±0.47） vs.（1.81 ±0.59）,drop asleep（1.44 ±0.52）vs.（1.90 ±0.50）,sleep lime（1.54 ±0.61） vs.（2.01 ±0.72）.sleep efficacy（1.24 ±0.53） vs.（1.72 ±0.65）,sleep disorders（1.15 ±0.49） vs.（1.55 ±0.62）.daytime function（0.92 ±0.45） vs.（1.71 ±0.58）,and total score（7.98 ±3.44） vs.（10.26 ±3.38）.The adverse events were similar between both groups（P〉0.05）.Conclusion The effectiveness of suvorexanl is superior to the estazolam lor treating ITIS with the similar adverse events.Thus,it deserves to apply in the clinic.

关 键 词：失眠 顽固性 苏沃雷生 艾司唑仑 疗效 安全性 

分 类 号：R740[医药卫生—神经病学与精神病学]